AU2021283916A1 - Kinase inhibitors - Google Patents
Kinase inhibitors Download PDFInfo
- Publication number
- AU2021283916A1 AU2021283916A1 AU2021283916A AU2021283916A AU2021283916A1 AU 2021283916 A1 AU2021283916 A1 AU 2021283916A1 AU 2021283916 A AU2021283916 A AU 2021283916A AU 2021283916 A AU2021283916 A AU 2021283916A AU 2021283916 A1 AU2021283916 A1 AU 2021283916A1
- Authority
- AU
- Australia
- Prior art keywords
- formula
- compound
- pharmaceutically acceptable
- isomer
- racemate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063033729P | 2020-06-02 | 2020-06-02 | |
| US202063033728P | 2020-06-02 | 2020-06-02 | |
| US202063033724P | 2020-06-02 | 2020-06-02 | |
| US63/033,724 | 2020-06-02 | ||
| US63/033,728 | 2020-06-02 | ||
| US63/033,729 | 2020-06-02 | ||
| US202163136593P | 2021-01-12 | 2021-01-12 | |
| US202163136587P | 2021-01-12 | 2021-01-12 | |
| US202163136577P | 2021-01-12 | 2021-01-12 | |
| US63/136,577 | 2021-01-12 | ||
| US63/136,587 | 2021-01-12 | ||
| US63/136,593 | 2021-01-12 | ||
| PCT/US2021/035509 WO2021247748A1 (en) | 2020-06-02 | 2021-06-02 | Kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021283916A1 true AU2021283916A1 (en) | 2023-01-05 |
Family
ID=76601840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021283916A Pending AU2021283916A1 (en) | 2020-06-02 | 2021-06-02 | Kinase inhibitors |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12448363B2 (https=) |
| EP (1) | EP4157446A1 (https=) |
| JP (2) | JP2023528421A (https=) |
| CN (1) | CN115867346B (https=) |
| AU (1) | AU2021283916A1 (https=) |
| CA (1) | CA3179637A1 (https=) |
| WO (1) | WO2021247748A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021398051A1 (en) | 2020-12-10 | 2023-07-27 | Principia Biopharma Inc. | Crystal form of tolebrutinib, preparation method therefor and use thereof |
| CN117915960A (zh) * | 2021-08-30 | 2024-04-19 | 百时美施贵宝公司 | 可用于布鲁顿酪氨酸激酶的pet成像的化合物 |
| WO2023227080A1 (zh) * | 2022-05-25 | 2023-11-30 | 百极弘烨(南通)医药科技有限公司 | 一种protac化合物、含其的药物组合物及其制备方法和应用 |
| JP2025521510A (ja) * | 2022-06-22 | 2025-07-10 | プリンシピア バイオファーマ インコーポレイテッド | 改変されたｂｔｋ阻害剤の作製方法 |
| CN116284025B (zh) * | 2023-02-20 | 2025-07-04 | 国科大杭州高等研究院 | 一种具有抗癌作用的螺杂环类化合物、药物组合物及其用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6509838B2 (ja) * | 2013-06-26 | 2019-05-08 | アッヴィ・インコーポレイテッド | Ｂｔｋ阻害薬としての一級カルボキサミド類 |
| EA034931B1 (ru) * | 2014-10-24 | 2020-04-08 | Бристол-Майерс Сквибб Компани | Индолкарбоксамидные соединения |
| SI3209651T1 (sl) * | 2014-10-24 | 2019-12-31 | Bristol-Myers Squibb Company | Derivati karbazola |
-
2021
- 2021-06-02 CN CN202180048117.5A patent/CN115867346B/zh active Active
- 2021-06-02 WO PCT/US2021/035509 patent/WO2021247748A1/en not_active Ceased
- 2021-06-02 EP EP21734730.1A patent/EP4157446A1/en active Pending
- 2021-06-02 AU AU2021283916A patent/AU2021283916A1/en active Pending
- 2021-06-02 JP JP2022574229A patent/JP2023528421A/ja active Pending
- 2021-06-02 US US18/007,705 patent/US12448363B2/en active Active
- 2021-06-02 CA CA3179637A patent/CA3179637A1/en active Pending
-
2025
- 2025-11-28 JP JP2025207773A patent/JP2026048716A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023528421A (ja) | 2023-07-04 |
| EP4157446A1 (en) | 2023-04-05 |
| CN115867346B (zh) | 2025-03-14 |
| WO2021247748A1 (en) | 2021-12-09 |
| CA3179637A1 (en) | 2021-12-09 |
| US20230219923A1 (en) | 2023-07-13 |
| CN115867346A (zh) | 2023-03-28 |
| JP2026048716A (ja) | 2026-03-17 |
| US12448363B2 (en) | 2025-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI877697B (zh) | 作為parp7抑制劑的嗒酮 | |
| US12448363B2 (en) | Kinase inhibitors | |
| CN104144930B (zh) | 新的中氮茚化合物，它们的制备方法以及包含它们的药物组合物 | |
| JP5121716B2 (ja) | ピリジン誘導体および精神異常の処置におけるそれらの使用 | |
| EP4712961A2 (en) | Kras g12s and g12c inhibitors | |
| WO2023061294A1 (zh) | 含氮杂环类衍生物调节剂、其制备方法及应用 | |
| CA3166554A1 (en) | Benzamide containing compounds for modulating brg1- or brm-associated factors_________________________________________________ | |
| TW202142542A (zh) | 藉由軛合ｂｔｋ抑制劑與ｅ３連接酶配位基降解布魯頓氏酪胺酸激酶（ｂｔｋ）及其使用方法 | |
| JP2022538019A (ja) | ＨＰＫ１阻害剤としてのピロロ［２，３－ｂ］ピラジン及びその使用 | |
| WO2017108723A2 (en) | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | |
| WO2022143856A1 (en) | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use | |
| JP2009507801A5 (https=) | ||
| CN106458912A (zh) | 双环稠合的杂芳基或芳基化合物以及它们作为irak4拟制剂的用途 | |
| TW202510858A (zh) | 治療自體免疫疾病之大環 | |
| EP3642204A1 (en) | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | |
| AU2021253584A1 (en) | Kinase inhibitors | |
| TW202517653A (zh) | 治療自體免疫疾病之大環 | |
| TW202417435A (zh) | 用於治療之parp14之靶向蛋白質降解 | |
| AU2022209175A1 (en) | Indole derivatives as kinase inhibitors | |
| WO2023230609A1 (en) | Heterocyclic pad4 inhibitors | |
| EA046667B1 (ru) | ПИРРОЛО[2,3-b]ПИРАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРА HPK1 И ИХ ПРИМЕНЕНИЕ | |
| HK1234395B (zh) | 双环稠合的杂芳基或芳基化合物以及它们作为irak4拟制剂的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: VIDYA THERAPEUTICS, INC. Free format text: FORMER APPLICANT(S): GB005, INC. |